Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.57 |
| ▸ | TP53 | P04637 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301393 | 0.87 | TP53 (0.65) | MAPTTP53SMN1; SMN2POLBNOTUM | |
| SCHEMBL31301653 | 0.82 | MAPT (0.66) | MAPTTP53SMN1; SMN2POLBNOTUM | |
| SCHEMBL2214252 | 0.82 | LMNA (0.45) | SMN1; SMN2POLBNOTUMLMNACNR1 | |
| SCHEMBL31301494 | 0.81 | MAPT (0.61) | MAPTTP53SMN1; SMN2POLBAURKA | |
| SCHEMBL31301448 | 0.81 | TP53 (0.77) | MAPTTP53SMN1; SMN2POLBLMNA | |
| SCHEMBL31301569 | 0.79 | MAPT (0.78) | MAPTTP53SMN1; SMN2POLBLMNA | |
| SCHEMBL2396935 | 0.78 | MAPT (0.47) | MAPTTP53SMN1; SMN2POLBNOTUM | |
| SCHEMBL31301433 | 0.78 | MAPT (0.70) | MAPTTP53SMN1; SMN2POLB | |
| SCHEMBL31301518 | 0.78 | MAPT (0.58) | MAPTTP53SMN1; SMN2POLBNOTUM | |
| SCHEMBL31301302 | 0.78 | MAPT (0.56) | MAPTTP53SMN1; SMN2POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | MAPT 4877/4885TP53 721/4885SMN1; SMN2 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.